Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL7763894 | 0.97 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1ALOX15 | |
| SCHEMBL28554464 | 0.87 | SLC7A5 (0.40) | SLC7A5SLC1A3SLC1A2SLC1A1KMT2A | |
| Asparagine SCHEMBL6130108 | 0.86 | ALOX15 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1ALOX15 | |
| SCHEMBL8695381 | 0.85 | NOS3 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1ALOX15 | |
| Aspartic Acid SCHEMBL28548999 | 0.84 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL891923 | 0.84 | SLC7A5 (0.55) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL2482058 | 0.83 | ALOX15 (0.53) | SLC7A5SLC1A3SLC1A2SLC1A1ALOX15 | |
| Valine SCHEMBL17582481 | 0.83 | SLC7A5 (0.37) | SLC7A5 | |
| Valine SCHEMBL17582472 | 0.83 | SLC7A5 (0.37) | SLC7A5 | |
| SCHEMBL1537267 | 0.81 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4331622-A2 | INTEGRIN BINDING PEPTIDES AND USES THEREOF | Universiteit Twente (NL) | 2024-03-06 | — | — | EP | disclosed |
| US-20240025965-A1 | INTEGRIN BINDING PEPTIDES AND USES THEREOF | PRAKASH JAI (NL) | 2024-01-25 | — | — | US | disclosed |
| US-20230407357-A1 | BIOMANUFACTURING OF OLIGOSACCHARIDES AND DERIVATIVES FROM SIMPLE SUGAR | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| WO-2023225364-A1 | BIOMANUFACTURING OF OLIGOSACCHARIDES AND DERIVATIVES FROM SIMPLE SUGARS | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3365353-B1 | INTEGRIN BINDING PEPTIDES AND USES THEREOF | UNIV TWENTE (NL) | 2023-11-22 | — | — | EP | disclosed |
| US-20230357318-A1 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS | MIMETOGEN PHARMACEUTICALS, INC. (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11753441-B2 | Solution phase synthesis of beta-turn peptidomimetic cyclic salts | MIMETOGEN PHARMACEUTICALS, INC. (CA) | 2023-09-12 | — | — | US | disclosed |
| US-11634470-B2 | Integrin binding peptides and uses thereof | Prakash, Jai (NL) | 2023-04-25 | — | — | US | disclosed |
| US-20210300966-A1 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS | MIMETOGEN PHARMACEUTICALS, INC. (CA) | 2021-09-30 | — | — | US | disclosed |
| US-11078234-B2 | Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts | MIMETOGEN PHARMACEUTICALS, INC (CA) | 2021-08-03 | — | — | US | disclosed |
| US-20150093799-A1 | HISTIDYL-TRNA SYNTHETASES FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | ATYR PHARMA, INC. | 2015-04-02 | — | — | US | disclosed |
| CN-101558309-B | A method of diagnosis and kit therefor | MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD | 2014-02-26 | — | — | CN | disclosed |
| WO-2013191926-A1 | SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS | MIMETOGEN PHARMACEUTICALS, INC. (CA) | 2013-12-27 | — | — | WO | disclosed |
| US-20130345395-A1 | SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS | MIMETOGEN PHARMACEUTICALS, INC. (CA) | 2013-12-26 | — | — | US | disclosed |
| WO-2012049453-A2 | COMPOSITIONS FOR TOPICAL APPLICATIONS | VECTUM PHARMA S.L. (ES) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011072264-A2 | METHODS AND COMPOSITIONS FOR BIOMASS TREATMENT | QTEROS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| CN-101558309-A | A method of diagnosis and kit therefor | MACFARLANE BURNET INST FOR MED (AU) | 2009-10-14 | — | — | CN | disclosed |
| CN-101090714-A | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | ACTELION PHARMACEUTICALS LTD (US) | 2007-12-19 | — | — | CN | disclosed |
| EP-1606309-A2 | ANTIMICROBIAL AGENTS FROM STREPTOCOCCUS MITIS AND STREPTOCOCCUS ORALIS | The University of Bristol (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004072093-A2 | ANTIMICROBIAL AGENTS FROM STREPTOCOCCUS MITIS AND STREPTOCOCCUS ORALIS | THE UNIVERSITY OF BRISTOL (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753441-B2 | Solution phase synthesis of beta-turn peptidomimetic cyclic salts | PNISR, CGAS, NGLY1 | SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885 |
| US-20210300966-A1 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS | PNISR, CGAS, NGLY1 | SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885 |
| US-20130345395-A1 | SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS | NGLY1, PTMS, CCNY | SLC7A5 2802/4885SLC1A3 4141/4885SLC1A2 4157/4885 |
| US-20230357318-A1 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS | PNISR, CGAS, NGLY1 | SLC7A5 2485/4885SLC1A3 3404/4885SLC1A2 3970/4885 |
| US-11078234-B2 | Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts | PNISR, RPP30, CXCL10 | SLC7A5 2316/4885SLC1A3 3862/4885SLC1A2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.